Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
Mayo Clinic
Beth Israel Deaconess Medical Center
Sellas Life Sciences Group
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Novartis
Children's Oncology Group
University of Minnesota